Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.
This meta-analysis suggests that for the treatment of proliferative lupus nephritis, MMF offers similar efficacy in renal remission and survival as cyclophosphamide with a better safety profile.
- Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial
- Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Management Study
- Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?